You are eating clean and training hard, but the mirror has stopped changing. Plateaus are where most cuts stall. Here is what the research literature covers on the peptides studied around fat loss and lean-mass retention.

Why plateaus happen

As covered in the appetite research, the body adapts to a deficit by lowering energy expenditure and raising hunger. At the same time, holding muscle during a cut becomes harder as calories drop. Recomposition, losing fat while preserving lean mass, is biologically demanding, which is why progress slows.

Peptides studied in this space

Different research compounds target different parts of the picture. The GLP-1 and dual or triple agonists are the most documented for reducing fat mass in controlled trials. Growth-hormone-axis peptides such as CJC-1295 and Ipamorelin have been studied for their effect on GH and IGF-1 signalling, which is relevant to lean tissue in research models. Recovery-focused peptides like BPC-157 appear in preclinical tissue-repair studies. Each sits at a different evidence stage.

What the research emphasises

No compound replaces the fundamentals that trials are built on: an appropriate protein intake, resistance training and a sustainable deficit. In the literature, peptides are studied as adjuncts within controlled protocols, not as substitutes for those inputs.

The bottom line

Plateaus are a predictable adaptation, and the research reflects a systemic approach. Continue with our overview of fat-loss peptides in research and why diets fail.

Research disclaimer▾

Alle informatie op deze pagina is bedoeld voor laboratoriumonderzoek en in-vitro studies. Geen humane consumptie. Geen medische claims. Producten zijn niet goedgekeurd door EMA of FDA voor therapeutisch gebruik.